Source BioScience and Oxford Gene Technology Collaborate to Deliver Next-Generation Sequencing Service
Source BioScience announced that it has acquired the next-generation sequencing services business from Oxford Gene Technology (OGT) in a move to expand its products and services portfolio.
Source BioScience announced that it has acquired the next-generation sequencing services business from Oxford Gene Technology (OGT) in a move to expand its products and services portfolio. The transfer of business from OGT to Source BioScience is hoped to contribute to the continued success and organic growth of the company.
Nick Ash, CEO of Source BioScience commented in a press statement that the company has forged a strong relationship with OGT and worked together on several projects. Ash said that with this acquisition, customers can now benefit from laboratory services from Source BioScience in conjunction with OGT’s analysis software.
According to Mike Evans, CEO of OGT, the company’s analysis software will be licensed to Source BioScience as part of the transfer, allowing customers continued access to the genetic analysis that OGT provides.
Source: Source BioScience
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
